Wyeth enters into partnership agreement to advance sustainable solutions to patient’s needs in UAE and other neighbouring countries
Wyeth (a Pfizer company), has signed a long-term partnership with UAE based Neopharma to locally manufacture selected pharmaceutical products here in the UAE, at a local event held in Abu Dhabi under the patronage of His Excellency Sheikh Nahyan Bin Mubarak Al Nahyan, Minister of Culture, Youth and Community Development in the United Arab Emirates.
The partnership aims to meet the unmet needs of patients and will focus primarily on diseases that residents suffer from across the region, such as cardiovascular diseases including hypertension and heart diseases. Other products include anti-inflammatory, pain management, women’s health and anti-infective drugs.
“This latest partnership highlights the importance Pfizer (through its Wyeth Company) places on our commitment to the UAE and wider Gulf region by providing reliable medication to our patients here on the ground. The strategic mix of Pfizer’s international experience with Neopharma’s local manufacturing capabilities enriches not only our presence here, but supports the UAE’s healthcare strategy by improving the quality of the healthcare systems provided to the greater benefit of the patients,” said Dr. Zeydan Abuissa, Country Manager & Pfizer Global Established Pharma Lead, Gulf and Levant.
“The partnership will enable us to transfer skills and knowledge locally as we foster, develop and successfully blending established international experiences with local unmet patients’ needs to enhance the UAE’s and the region knowledge based economy and develop local talent,” added Dr. Zeydan.
Commenting on the partnership, Dr. B.R. Shetty, Founder, Managing Director and CEO, Neopharma, said, “With Pfizer (through its Wyeth Company) and Neopharma working together, we witness the formation of collaborative efforts across manufacturing and distribution. This partnership will allow Pfizer’s research driven process and Neopharma’s world class manufacturing and regional expertise to work in synergy to make Abu Dhabi a hub in bringing leading therapies to the regional markets. For me personally this is a dream come true and an important milestone in contributing back to Abu Dhabi which has been my motherland for 42 years now.”
From his side, Mr. Marwan Abdulaziz, Executive Director of DuBiotech, part of TECOM Investments who attended the ceremony said, “I am delighted to be witnessing this partnership as it characterises the UAE’s rapidly developing pharmaceutical industry and also strengthens the sector’s domestic production capabilities. We at DuBiotech, understand the importance of supporting manufacturing, research and development in the UAE to decrease the reliance on imports in the healthcare industry, and will continue to provide a platform that fosters a culture of collaboration among peer companies, ultimately to ensure that such partnerships translate to better healthcare for our nation – one of the top priorities on the UAE Government agenda.”
The official signing ceremony of the partnership agreement was held at the Ritz Carelton Hotel Abu Dhabi and attended by Mr. John Young, Group President of Pfizer’s Global Established Pharma business; Mr. Guy Lallemand, Pfizer’s Regional President for Africa and the Middle East, and key members of Pfizer’s regional and UAE leadership team.
The medicines which will be produced at Neopharma’s production plant in Abu Dhabi and will be available in many markets in the region starting in the market in 2015.
For media enquiries contact: